Linked Life Data

17404197

Source:http://linkedlifedata.com/resource/pubmed/id/17404197

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2007-4-3
pubmed:abstractText
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
3
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1144-6
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Intravenous immunoglobulin therapy for Miller Fisher syndrome.
pubmed:affiliation
Department of Neurology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan. morim@faculty.chiba-u.jp
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't